Abstract: To observe the effects of reduced glutathione on promoting osseointegration of titanium implants in New Zealand rabbits with type I diabetes mellitus and to provide novel evidence for improving implants osseointegration. Diabetes mellitus models were established by injecting alloxan (80 mg/kg) into New Zealand rabbits. Success was verified by the blood glucose level. Titanium implants were then placed in the rabbits' femoral epiphysis. Intravenous glutathione (GSH, 30 mg/kg) or saline, respectively, was started. The rabbits were divided into four groups: GSH-treated diabetes mellitus (GSH+DM), diabetes mellitus (DM), GSH-treated normal rabbits (GSH), normal control rabbits (NC). Four weeks after surgery, the rabbits were evaluated via general observation, micro-computed tomography (micro-CT), H&E staining and bone morphogenetic protein 2 (BMP-2) immumohistochemical staining. In results, general observation and micro-CT showed that wounds had healed, no implants had loosened, and there was good synostosis in all groups. Micro-CT also revealed that peri-implant threaded bone density was higher than that in peri-implant cancellous bone and was similar to that in femoral cortical bone. The implants tightly fused with surrounding bone tissue. HE staining revealed that large numbers of bone trabeculaes, osteoblasts, and chondrocytes in the GSH+DM group and granulation tissue, mononuclear macrophages, and multinucleated giant cells in the DM group. New bone trabecular formation was rare. There was greater expression of BMP-2 in the GSH+DM group than in the GM group. The results suggest that GSH promotes new peri-implant bone formation and osseointegration in diabetic rabbits.
Introduction
Implants have become the ideal repair method for dentition defects and the edentulous jaw. Several systemic diseases, however, affect the process of implant osseointegration and greatly restrict the application of implant technology. The prevalence of diabetes mellitus (DM) is increasing sharply, with an estimated 380 million people (7.3 %) developing it by 2025 1) -up from 246 million cases (6 %) in 2007. An increasing number of DM edentulous patients are requiring dental implantation, but the success rate of dental implantation in diabetic patients has been significantly lower than that in the normal population (10-year survival rate 85.6-88.8 % vs. 98 %), 2) which hinders further application of implant technology. DM-induced chronic hyperglycemia affects various tissue structures and produces inflammatory cytokines, which stimulate bone resorption, inhibit osteoblast differentiation, alter the parathyroid hormone response, and influence bone metabolism, thereby reducing the formation of bone matrix and playing a crucial role in extracellular matrix adhesion, growth, and aggregation 3) . Chronic hyperglycemia reduces peri-implant bone tissue formation and is associated with horizontal or vertical bone defects. After implantation, osseointegration is incomplete, the healing time is prolonged, new bone is immature, and no fiber-implant contact is formed. Diabetes mellitus has been consistently associated with deficient metabolism of the skeletal tissue, which, especially in T1DM, is primarily related to suppressed osteoblastic activity and reduced bone formation potential, irrespectively of the type of bone, the location and the mechanical loading characteristics 3) . Although the success and failure rates of implantation in DM patients have been studied extensively, only a few studies have focused on the effects of insulin treatment on implant osseointegration in these patients. Their results have suggested that insulin therapy could improve peri-implant bone formation and enhance new bone formation. Wang et al. 4) found that local sustained applica-
J.Hard Tissue Biology Vol. 24(3):277 -284, 2015
Oxidation is highly involved in the antioxidant imbalance in DM patients. When implants are placed in alveolar bone, the body is being stressed and the intracellular level of reactive oxygen species rises, exceeding the scavenging capacity. A large amount of reactive oxygen species not only can directly attack cell proteins, lipids, nucleic acids, and other components, it activates a variety of intracellular signaling pathways that promote inflammation, accelerate extracellular matrix secretion, induce apoptosis, and accelerate synthesis of reactive oxygen species 3) . Glutathione (GSH) is involved in the tricarboxylic acid cycle in vivo, activates various enzymes, and exerts antioxidation effects. As an important metabolism regulator and antioxidant, GSH scavenges oxygen free radicals, enhances antioxidant enzyme activity, and improves the body's defense capacity. It has therefore been widely applied in the drug treatment and adjuvant therapy of a variety of multi-system, multi-organ diseases, such as those involving liver or kidney damage as well as eye disease, cardiovascular disease, and
Parkinson's disease [5] . The present study aimed to explore the effects of antioxidant GSH intervention on implant osseointegration and provide an applicable solution to promote osseointegration efficiency for individuals in DM patients
Materials and Methods

Materials and equipment
The study included 20 male clean-grade 5-month-old New Zealand white rabbits weighing 2. 
Model establishment and animal grouping
The involved rabbits were randomly given intravenous injections of GSH (30 mg/kg) or saline, respectively, and were divided into four groups: GSH-treated diabetes mellitus (GSH+DM), diabetes mellitus (DM), GSH-treated normal rabbits (GSH), normal control rabbits (NC).
After the rabbits were fed standard diet for 2 weeks, their blood glucose levels were determined prior to modeling. Animals were fasted for 8 h and fixed on the operation table, exposing the head and ears. The ear veins were disinfected with 75% alcohol and allowed to expand fully. Then, alloxan (50 mg/ml, 80 mg/kg per week for a total of three injections) was slowly injected into the ear veins. The control group was given injections of normal saline. The blood glucose level was recorded at 2, 4, and 6 h after administration, and 10 mL of glucose injection and glucose solution (100 g/l) were injected within 24 h if needed to prevent hypoglycemia. During establishment of the model, blood glucose levels were monitored as following method every 24 h. When the fasting blood glucose level was higher than 19.4 mmol/l, the rabbits were given subcutaneous injections of insulin (1-4 U/kg).
All the rabbits were fed standard diet throughout the trials. The success of creating a DM model was defined as accomplished by a fasting blood glucose level of >13.9 mmol/l. The fasting blood glucose levels reached their peak 2 weeks after injection of alloxan and were maintained at 14. 
Dental implantation
Rabbits were anesthetized with intramuscular injection of sumianxin (0.1 ml/kg) and fixed in the supine position on the operating table. After the skin was disinfected and covered with a sterile towel, a 1.0-cm incision was cut on the left leg under local anesthesia of 0.5% lidocaine injection (2 mL containing epinephrine 4 ìg/ml). The incision was into the right medial femoral epiphysis, exposing subcutaneous tissue and bone surface. A titanium implant (3.8 mm diameter, 5.0 mm length) was placed into the implant bed (2.0 mm diameter, 5.0 mm depth), which had been previously prepared at a speed of 1800 rps following continuous saline cooling. The titanium implant (SUNTEC Titanium Co., Ltd., Dalian, China) was in large particles with a blasting-etched surfaces. To the naked eye, SLA-treated Ti samples had a rough surface that exhibited no metallic luster and was dark gray in color. After mechanical polishing, there were uniform scratches on the surface of Ti, as observed under the scanning electron microscope. After SLA treatment, micro-level macropores with a pore size of 80-90 µm (grade A pores) and micropores with a pore size of 2-8 µm (grade B pores) were visible on the sample surface. Grade A pores were produced from strikes by corundum sands during sandblasting and were round or oval, and shallow and concave in shape; grade B pores were produced from etching and were round or oblong with sharp edges, but regular in size Jingying Zhang et al.: Reduced Glutathione Promotes Implant Osseointegration and shape, which is shown in Fig.1 .
After implantation, the periosteum, subcutaneous tissue, and skin wound were sutured. The rabbits were housed in separate cages and allowed free activity. Intramuscular injection of penicillin (400,000 units) was given daily for 7 days. Blood glucose levels were monitored, and an appropriate amount of subcutaneous insulin (1-4 U/kg) was given if necessary to ensure a blood glucose level within the experimental range (higher than 19.4 mmol/l).
General observation and micro-computed tomgraphy scanning
Rabbits were killed with an overdose of sumianxin (0.4 ml/ kg) via intramuscular injection at 4 weeks after surgery. The rabbit femurs with the implants were dissected, and peri-implant bone tissue healing and growth were observed under micro-computed tomography (CT) (Siemens, Malvern, PA, USA).
Decalcified bone tissue preparation
The rabbits were killed 8 weeks after surgery. Their femurs were harvested, and the implants were removed and fixed in 4 % formalin. The fixed bone tissue was rinsed with saline and decalcified with 20 % EDTA solution in a microwave oven (50°C ). The decalcification process was intermittent, with each decalcification cycle consisting of 2 min of irradiation for a total of 30 cycles. Specimens were cooled at room temperature in a water bath for 2 min between cycles to ensure that the temperature of the decalcification solution was lower than 70 °C during irradiation. After bone decalcification, specimens were treated with a series of procedures, including conventional dehydration, transparency, soaking in wax, and embedding, They were then made into 5 ìm thick slices, mounted, and dewaxed. The decalcification method in accordance with the HE staining instructions of Beijing Beijing-shirt Bridge Biotechnology Co. The slices were stained with HE and photographed under an optical microscope.
Immunohistochemical staining of BMP-2 expression
Paraffin sections were deparaffinized and incubated in 3 % H 2 O 2 deionized water for 10 min to eliminate endogenous physical activity. They were then rinsed with distilled water and immersed in phosphate-buffered saline (PBS) for 5 min followed by hightemperature antigen retrieval. The sections were incubated with reagent A (blue liquid) at room temperature for 10 min, incubated with antibodies (1:100) at 4 °C overnight, and rinsed with PBS for 3 min three times, incubated with reagent B (yellow liquid) at room temperature for 10 min, and rinsed with PBS for 3 min three times. They were then incubated with reagent C (orange liquid) at room temperature for 10 min and rinsed with PBS for 3 min three times. Specimens were developed with a chromogenic reagent (DAB), rinsed thoroughly with tap water, and counterstained. The cell nuclei were dehydrated and transparent. Specimens were mounted and observed under an optical microscope. Images were acquired.
Results
Establishment of alloxan-induced DM models
After intravenous injection of ALX 24-48h rabbits appear apathetic, decreased activity, loss of appetite symptoms, significant weight loss occured one week after. Blood glucose levels in rabbit ear venous blood were recorded at 1 and 4 weeks after injection.
Results showed that blood glucose levels were >16.7 mmol/L, which was significantly higher than the baseline level and that for the normal control group (Table 1) . It was evidence that indicated successful establishment of the DM models. Two rabbits died of convulsions after the alloxan injection. The 18 healthy rabbits that survived met the standard of modeling success. Body weights of the rabbits were significantly reduced after injection, with apparent emaciation. The body weights before and after the injection were significantly different (P<0.01) ( Table 2) .
Implant healing
The wounds were well healed in all four groups. No ulceration was found, the implants fused with surrounding bone tissue without loosening, and the tapping sound was crisp (Fig. 2) . Micro-CT scanning revealed that the peri-implant threaded bone density was higher than the peri-implant cancellous bone density and was similar to the femoral cortical bone density. The implants had tightly fused with the surrounding bone tissue (Fig. 3) , with no significant differences among the four groups. 
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HE staining
As shown in Fig. 4 , at 8 weeks after implantation, bone tissue hematoma had not disappeared in the DM+GSH group, granulation tissue had frown into the fracture site, probably because subperiosteal bone progenitor cells had proliferated, and mesenchymal cells had aggregated. In the DM group, a large amount of bone trabeculae and some osteoblasts and chondrocytes were visible. there was more granulation tissue and little new trabecular bone formation. There were also more mononuclear macrophages and multinucleated giant cells. In the GSH group, trabecular bone had integrated in patches, and the trabecular bone had begun to mold and transform into lamellar bone. Fibrous callus had disappeared. In the NC group, trabecular bone had fused, and cartilage callus was replaced by new trabecular bone. Fibrous callus was still visible.
BMP-2 immunohistochemical staining
As shown in Fig. 5 , at 4 weeks after implantation BMP-2 expression was strong in fibroblasts, osteoblasts, mature chondrocytes, and bone matrix in the DM+GSH group. In the DM group, BMP-2 was found in the same cells but with reduced expression. In the GSH group, BMP-2 was expressed in osteoblasts, osteoclasts, and bone matrix. In the NC group, BMP-2 expression was seen in some osteoclasts and was weakly positive in bone matrix.
Discussion
Experimental DM is produced by various methods, including
inflicting damage to the pancreas or islet â cells, leading to insulin deficiency or with a variety of insulin antagonists. DM animal models include pancreatectomy-induced diabetes, chemical diabetes, autoimmune diabetes, viral diabetes, spontaneous diabetes, and transgenic diabetes. At present, streptozotocininduced diabetic rats are the most commonly used animal models in the field of DM. As rabbits are not sensitive to streptozotocininduced diabetes, type I diabetic rabbit models are often established through intravenous injection of alloxan alone or alloxan combined with streptozotocin. Alloxan is a cytotoxic agent that selectively damages islet cells in a variety of animals, triggering experimental diabetes. After injection of alloxan, changes in the animal's blood glucose levels are divided into three phases: (1) an early, transient (approximately 1-4 hours) hyperglycemic period that is related to stress; (2) a hypoglycemic period caused bycell destruction and insulin release, lasting 48 h and sometimes causing convulsions and death; (3) persistent hyperglycemia caused by -cell damage after 48 h and the appearance of DM.
We selected the dose of the alloxan injection dose according to the rabbit's weight (80 mg/kg). It effectively destroyed the rabbit's pancreatic cells and induced a diabetic state. This dose avoided the animal's death that occurs with large doses of the drug. The standard for blood glucose levels in DM animals is inconsistent, mostly in the range of 11.1-16.7 mmol/L. Growing evidence has tended to define the fasting or nonfasting blood glucose levels at 11.1-16.7 mmol/L for successful creation of DM models. In this study, the successful DM model was defined based on a fasting blood glucose level >16.7 mmol/l.
During dental implantation, host tissue reactions include a series of cellular and molecular processes during tissue healing and fracture repair. Bone tissue molding and remolding can be achieved through implant-bone surface fusion guided by osteoblasts and osteoclasts. Undifferentiated mesenchymal cells and progenitor cells migrate from the surrounding bone marrow, endosteum, and periosteum to the implant and proliferate. Under the action of local growth factors, these cells differentiate into osteoblasts or osteoclasts, which form osteoid tissue and, subsequently, mature bone. Histological findings have shown that active osteoclasts, thinning cortex, and thinning and sparse trabecular bone are present in the bone tissue of DM animals.
Also, the number of osteoblasts are reduced, and the osteoblasts are flat or star-shaped. New bone formation is rarely seen 6) . The reduced number of osteoblasts, inadequate osteoid formation, and slow bone deposition and mineralization contribute to bone remodeling and affect peri-implant bo ne density and osseointegration.
The mechanism of bone loss in DM remains unclear. Recent studies have shown that insulin deficiency, insulin-like growth factor reduction, inflammatory cytokine interleukins, tumor necrosis factor, and other factors may lead to decreased osteoblast activity and numbers, functional dysfunction, and collagen synthesis disorders, ultimately resulting in bone formation disorders 2) . GSH is a good antioxidant synthesized naturally in human cells. It can be utilized and recycled via the glutamate recycling system. GSH, which consists of glutamic acid, cysteine, and glycine, can directly eliminate H 2 O 2 , eliminate toxic metabolites produced by reactive oxygen species, and repair oxidative damage. It can also directly protect -SH without biotransformation, serve as a hydrogen donor to promote peroxidase reduction reactions catalyzed by GPx, CAT, and SOD enzymes, directly scavenge free radicals, increase free radical scavenging activity, enhance the body's antioxidant defense capacity, and attenuate oxidative damage 7) . GSH is critically involved in the regulation of lipopolysaccharide-induced cytokine transcription and the I-KB/NF-B signaling pathway. It plays an important role in cell signaling of reactive oxygen species under oxidative stress and prevents the oxidative stress response by adjusting the Ca 2+ concentration in mitochondria. Reduced GSH can prevent Ca 2+ overload in neurons and activate glutamate receptors in neurodegenerative diseases 8) . At present, reduced GSH has been widely applied in the drug treatment and adjuvant therapy of a variety of multi-system, multi-organ diseases such as those associated with liver and kidney damage, eye diseases, and cardiovascular diseases 9) . As an antioxidant, reduced GSH lowers the activity of redox-sensitive NF-kB, inhibits inflammatory cytokines (e.g., tumor necrosis factor-, interleukin-6, interleukin-8), and attenuates oxidative stress injury 10) . In this study, after diabetic rabbits were given intravenous injections of reduced GSH for 4 weeks, there was no significant difference between groups according to the results of general observation or micro-CT scanning. Peri-implant bone tissue grew well. Histological findings showed that intravenous injection of reduced GSH produced more osteoblasts and chondrocytes than did saline injection, new bone trabecular formation was faster, and trabecular bone began to mold and transform into lamellar bone. Also, there was greater expression of BMP-2 than in the saline-injected groups. This evidence indicates that the speed and degree of new bone formation were better after the GSH intervention than after saline injection. GSH is therefore regarded as a potential approach to improving implant osseointegration in DM patients. We believe that we have provided novel evidence that there is a way to increase the implantation success rate.
